Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
23
datasets available to search
ShareScore release 0.9.0
Dataset results
23 results for “Tumor Mutational Burden”
The burden of post-translational modification (PTM) – disrupting mutations in the tumor matrisome
<p>A Pan-cancer analysis of the post-translational modification (PTM) – disrupting mutations in the tumor matrisome</p>
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
ClinicalTrials.gov study NCT03668119. IPD Sharing: NO. Countries: 17. Publications: 1.
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
ClinicalTrials.gov study NCT02553642. IPD Sharing: Not stated. Countries: 1. Publications: 1.
DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden
GEO Series GSE268555. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
Characterization of tumor mutational burden in LKB1 mutant lung tumors
GEO Series GSE137244. Mus musculus. 11 samples. Type: Expression profiling by high throughput sequencing.
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy
GEO Series GSE277573. Homo sapiens. 100 samples. Type: Methylation profiling by array.
Autophagy Promotes Growth of High Tumor Mutational Burden Tumors by Inhibiting a T Cell Immune Response
GEO Series GSE155557. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing; Other.
DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden
GEO Series GSE285341. Mus musculus. 4 samples. Type: Other.
DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden
GEO Series GSE289119. Mus musculus. 6 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Autophagy Promotes Growth of High Tumor Mutational Burden Tumors by Inhibiting a T Cell Immune Response [RNA-seq]
GEO Series GSE154654. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
The association between tumor mutational burden and prognosis is dependent on treatment context
<p>This dataset has been used to analyze the association between high tumour mutational burden and survival in immunotherapy-treated and non–immunotherapy-treated patients with cancer. The dataset contains clinical and genomic data for 10,233 patients with 17 cancer types.</p>
Harmonization of Tumor Mutation Burden testing
<p>Dataset of the different TMB values obtained with the CGP assays.</p>
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsat
ClinicalTrials.gov study NCT06331598. IPD Sharing: YES. Countries: 1. Publications: 0.
Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden
ClinicalTrials.gov study NCT03671720. IPD Sharing: NO. Countries: 1. Publications: 0.
Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group T
ClinicalTrials.gov study NCT03492918. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Tumor Mutational Burden in Lung Cancer Patients
ClinicalTrials.gov study NCT04289259. IPD Sharing: YES. Countries: 1. Publications: 0.
Interference of tumor mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: A multicenter retrospective study of the German Cancer Consortium Rad
GEO Series GSE122272. Homo sapiens. 37 samples. Type: Expression profiling by array.
Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia
GEO Series GSE160499. Homo sapiens. 7 samples. Type: Expression profiling by high throughput sequencing.
Autophagy Promotes Growth of High Tumor Mutational Burden Tumors by Inhibiting a T Cell Immune Response [Exome-seq]
GEO Series GSE155556. Mus musculus. 4 samples. Type: Other.
Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burden
GEO Series GSE211592. Homo sapiens. 24 samples. Type: Other.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.